in our free newsletter.

Thousands benefit from our email every week.

Colgate-Palmolive (CL)

It’s easy to see why Colgate-Palmolive belongs to a recession-resistant portfolio.

The company is deeply entrenched in its operating markets, including oral care, personal care, pet nutrition and home care.

Notably, its leading brand Colgate has by far the largest share in the toothpaste market worldwide. And thanks to brands like Softsoap and Palmolive, the company is also a dominant player in the liquid soap market.

No one is going to stop buying soap or toothpaste in tough times. That simple truth has led to a long and consistent track record of returning cash to investors.

The company has increased its payout for 60 consecutive years.

Business is still growing: In Q1, organic sales at Colgate-Palmolive increased 4% year-over-year.

Paying quarterly dividends of 47 cents per share, CL stock offers an annual yield of 2.5%.

Contemporary art has outperformed the S&P 500 by 131% for the past 26 years. Join the exclusive platform to invest in million-dollar works by artists like Banksy, Basquiat, and more. Get started today and diversify your portfolio with art.

Learn More

WM (WM)

Formerly known as Waste Management, WM brands itself the largest comprehensive waste management environmental solutions provider in North America. It says it provides collection, recycling and disposal services to more than 20 million residential, commercial, industrial and municipal customers.

Waste management is not an exciting business, but it is an essential one: Whether the economy is booming or in a recession, people still need someone to come and collect their garbage.

The company was founded in 1968 and is still cleaning up today.

In Q1, WM’s revenue grew 13% year over year to $4.66 billion. Adjusted earnings per share came in at $1.29 for the quarter, up 22% from the year-ago period.

WM currently pays quarterly dividends of 65 cents per share — 13% higher compared to what it was paying a year ago. That makes 2022 the 19th consecutive year that the company has raised its payout.

The stock offers an annual yield of 1.9%.

Johnson & Johnson (JNJ)

With established positions in consumer health, pharmaceuticals and the medical devices markets, health-care giant Johnson & Johnson has delivered regular returns to investors throughout economic cycles.

Many of the company’s consumer health brands — such as Tylenol, Band-Aid and Listerine — are so ubiquitous they’re used as shorthand for their entire product category. In total, JNJ has 29 products each capable of generating over $1 billion in annual sales.

Not only does Johnson & Johnson post recurring annual profits, but it also grows them consistently: Over the past 20 years, Johnson & Johnson’s adjusted earnings have increased at an average annual rate of 8%.

The stock has been trending up for decades. And it is demonstrating its resilience again in 2022: While the broad market has entered bear territory, JNJ is down just 1.2% year to date.

JNJ also announced its 60th consecutive annual dividend increase in April and now yields 2.7%.

Meet Your Retirement Goals Effortlessly

The road to retirement may seem long, but with WiserAdvisor, you can find a trusted partner to guide you every step of the way

WiserAdvisor matches you with vetted financial advisors that offer personalized advice to help you to make the right choices, invest wisely, and secure the retirement you've always dreamed of. Start planning early, and get your retirement mapped out today.

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.

What to Read Next

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.